Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Industry News

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

October 17, 2020

Presentation TCT 2020

COBRA-REDUCE: Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy

Presenter: Robert A. Byrne

October 17, 2020

Presentation TCT 2020

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Presenter: Robert Byrne

October 17, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

News Opinion Editor's Corner TCT 2020

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

Shelley Wood

October 09, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Industry News

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

June 01, 2020

Video

» Interview

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

October 17, 2020

Advertisement

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

COBRA-REDUCE: Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content